To help with the efficient management of all our clinical trials, Accelagen has partnered with SureClinical to gain access to their range of electronic trial management tools, commencing with the SureClinical eTMF.

In April of this year, SureClinical announced a complimentary COVID-19 eClinical application program to support medical research into COVID-19 vaccines and treatments. Through this offering, SureClinical has been selected to support Accelagen’s important Phase 1/2 trial with access to its eClinical Cloud Suite, helping to find the fastest path to a commencing study start up and conduct.

Through using SureClinical’s tools, SureClinical has assisted Accelagen with reducing the time and resources needed to activate the study and ensure all steps are completed efficiently. Their tools provide our Project team with an easy to use method to collect, record and track essential documents. “We are very grateful to SureClinical for their support of our critical work in this crucial trial. Using SureClinical, we are confident to be able to accelerate our study startup and improve trial management for our critical study to find effective treatments for COVID-19 patients”, says Greg Plunkett, Managing Director of Accelagen.

Accelagen will continue to utilise the SureClinical platform for all studies going forward, thereby providing our clients with a robust, easy to use and valuable tool for clinical trial management.

Please get in touch to see how we can assist with future trials.